Company intelligence / Profile preview

OncoSec Medical

San Diego, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

OncoSec's lead candidate TAVO-EP (plasmid encoding IL-12) is in Phase 3 trials for metastatic melanoma. The KEYNOTE-695 trial is evaluating TAVO-EP in combination with Merck's Keytruda in melanoma patients refractory to immune checkpoint therapy. Top-line results for the secondary endpoint (ORR by investigator assessment) were expected in Q4 2022, and primary endpoint results (ORR by blinded independent review) were expected in Q1 2023.

Therapeutic areas: Oncology
Modalities: Gene therapyDNA-based immunotherapyPlasmid-based therapy
Industry: Biotech

Drug pipeline

10 assets

tavokinogene telseplasmid

9 more assets in the full pipeline.

Request access →

Partnerships

Merck (for KEYNOTE-695 and KEYNOTE-890 trials with Keytruda)Bristol-Myers Squibb (for trials with Opdivo)

Beyond the preview

Go deeper on OncoSec Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoSec Medical.

Explore the full profile